Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.

To determine the visual outcome following initiation of brimonidine therapy in glaucoma.
16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%. Visual acuity, contrast sensitivity (CS), visual fields, intraocular pressure (IOP), blood pressure, and heart rate were evaluated at baseline and after 3 months.
IOP reduction was similar for both groups (p<0.05). Brimonidine improved CS; in the right eye at 6 and 12 cpd (p=0.043, p=0.017); in the left eye at 3 and 12 cpd (p=0.044, p=0.046). Timolol reduced CS at 18 cpd in the right eye (p=0.041). There was no change in any other measured parameters.
Glaucoma patients exhibit improved CS on initiation of brimonidine therapy.
AuthorsD W Evans, S L Hosking, D Gherghel, J D Bartlett
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 87 Issue 12 Pg. 1463-5 (Dec 2003) ISSN: 0007-1161 [Print] England
PMID14660453 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic alpha-Agonists
  • Adrenergic beta-Antagonists
  • Quinoxalines
  • Receptors, Adrenergic, alpha-2
  • Brimonidine Tartrate
  • Timolol
  • Adrenergic alpha-Agonists (therapeutic use)
  • Adrenergic beta-Antagonists (therapeutic use)
  • Analysis of Variance
  • Brimonidine Tartrate
  • Contrast Sensitivity
  • Glaucoma, Open-Angle (drug therapy, physiopathology)
  • Humans
  • Intraocular Pressure (drug effects)
  • Middle Aged
  • Quinoxalines (therapeutic use)
  • Receptors, Adrenergic, alpha-2 (drug effects)
  • Timolol (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: